• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Disparities remain an obstacle to health equity in eye care

Publication
Article
Digital EditionOphthalmology Times: September 2023
Volume 48
Issue 9

Leaders must confront issues perpetuating unequal access, unfair practices.

(Image Credit: AdobeStock/freshidea)

(Image Credit: AdobeStock/freshidea)

Reviewed by Mildred M.G. Olivier, MD

“Of all the forms of discrimination and inequality, injustice in health care is the most shocking and inhumane because it often results in physical death.”
Martin Luther King Jr

This quote cuts to the heart of the matter, but Mildred M.G. Olivier, MD, speaking recently at the National Medical Association’s 121st Annual Convention and Scientific Assembly, explained that other issues come into play before a meaningful discussion of this important topic can take place. Olivier is associate dean of the School of Medicine at Ponce Health Sciences University in St Louis, Missouri.

Emotions can run deep

Olivier explained that when the topic of inequity is broached, complex feelings often emerge, including guilt, anger, resentment, and defensiveness. “You may perceive me of accusing you of being racist [or] sexist,” she said. “You may feel I have a specific political agenda or that I lack objectivity.” However, she noted, if health profession leaders cannot acknowledge and process these difficult emotions, how can they expect others to do so?

“Health professionals are not taught about the connections between white supremacy, oppression, injustice, and health,” Olivier said. “We have been socialized to believe that it is not polite to talk about racism, injustice, and oppression.”

She enumerated multiple educational objectives involving discussions of structural and personal racism, racial and ethnic health disparities, big data, importance of data collection in clinical trials, and education of patients and colleagues. The objective is to examine and dismantle racism head-on and not sidestep the issue on institutional/structural, personally mediated, and internalized levels. “We must examine structures, policies, practices, norms, and values to determine how racial inequities are being maintained and how could race be operating here,” Olivier said.

Disparities in the health care arena

Olivier defined a health disparity as a difference, based on 1 or more health outcomes, that adversely affects members of a defined disadvantaged population. The difference is perpetuated by social injustice in which public and institutional practices, cultural representations, and other norms work to reinforce perpetuation of racial group inequities.

The most important component of this is the defined populations. These populations are designated by the US Congress, she stated.

Social determinants of health (ie, economic stability, neighborhood and physical environment, education, food, community/safety/social context, and health care system) involve inequality relating to health-damaging experiences resulting from the “toxic combination” of poor social policies, unfair economic arrangements, and bad politics.1 All of the elements involved in the social determinants of health interact to determine morbidity, mortality, life expectancy, health care expenditures, health status, and functional limitations.

What is the issue?

She posed 2 questions. Do new medications, devices, and surgical procedures allow equal access for those who are underrepresented? Do underrepresentation in research and overrepresentation in incidence and prevalence of disease have a role?

A quick look at 2 breast cancer statistics illustrates the point: Olivier noted the death rate is 41% higher for Black women compared with White women, and only 6% of Black women participate in breast cancer clinical research. Olivier explained that not all segments of the population have benefited from advances in science and medicine, and the disparities in clinical and genomic research are well characterized. In addition, she said, distinct populations have been understudied in science, underrepresented in research, and underserved by medicine. Also, data representative of real-world patient populations are required to optimize clinical outcomes for all patients. The data show that 8% of the global population participates in clinical research, 80% of the participants are Caucasian, and 91% of the genomics databases only contain data from patients of European ancestry.

The NIH (National Institutes of Health) Revitalization Act of 1993 mandates the inclusion of women and members of minority populations in all NIH-funded clinical research as appropriate to the studies undertaken. The law’s primary goal is to ensure that research findings are generalizable to the entire population. To meet this end, clinical trials must be designed to provide information about differences by sex/gender, race and/or ethnicity. Despite this, the awareness of health disparities in clinical trials remains well recognized.

Disparities in vision health and eye care

The American Academy of Ophthalmology Taskforce on Disparities in Eye Care2 identified the following issues: Members of minority populations face higher risk of ocular diseases, visual impairment, and blindness; older individuals are more at risk and disproportionately affected; sex and gender differences exist in eye care; and older Hispanic patients and others use fewer low-vision devices.

Regarding sociodemographics and diseases, the following problems have been identified:

  • Complex cataracts have disproportionately higher prevalence rates in patients who are Black, Hispanic, or Chinese American.
  • Lower rates of cataract surgeries performed among Black or Hispanic patients.
  • Black patients are more likely to develop anterior uveitis after cataract surgery.
  • Patients who are Native American are at greater risk for developing endophthalmitis after cataract surgery.
  • There is a higher burden of glaucoma with older patients.
  • Higher rates of glaucoma surgery are performed due to underdiagnosis and later patient presentation.
  • Higher prevalence rates of glaucoma are seen in Hispanic and White women, and in Asian American patients.
  • Higher glaucoma surgical failure rates are seen in non-White populations.
  • Minimally invasive glaucoma surgery (MIGS) does not show a difference, but the number of patients who underwent MIGS is too small to be definitive.

Primary open-angle glaucoma

This is the most common form of the disease across all patient populations. However, African American patients are 5 to 6 times more likely to have primary open-angle glaucoma (POAG) compared with European American patients. In addition, POAG develops 10 years earlier and progresses more rapidly in African American patients, making it the leading cause of irreversible blindness in this population.

Retinal disease

In addition to glaucoma, Olivier described the inadequate treatment response to antivascular endothelial growth factor therapy for diabetic macular edema:

  • Among those with diabetes, the prevalence of diabetic retinopathy was 33.4% in Hispanic patients and 26.5% in Black patients compared with 18.2% in White patients.2
  • Native American patients have one of the highest prevalence rates of DR, with a rate of 45.3% compared with non-Native American populations.2
  • Black patients also had an increased risk of developing moderate/severe DR compared with Caucasian patients.1
  • Compared with Caucasian patients, Black patients and Hispanic patients have increased insulin resistance and augmented insulin secretion/hyperinsulinemia independent of adiposity.3

The future

Olivier placed the burden squarely on clinicians and urged that data continue to be collected from underserved populations; that clinicians continue to acknowledge and pilot interventions to address social determinants including systemic racism; that they build infrastructure to identify modifiable determinants at multiple levels; that they elevate community voices, formulating ways to increase underrepresented population participation in clinical trials and genomic databases; and that they increase diverse populations to improve scientific understanding of various ophthalmic conditions and improve the standard of care for all patients.

  • Recruitment of Black and Hispanic ophthalmologists is a pressing need. She enumerated the barriers to recruitment:
  • There is a need to create new points in the databases to get the information needed.
  • There is a need to educate ophthalmologists on needing data and encouraging representation in trials that are diverse.
  • There is a need for unconscious bias training to increase awareness and not make judgments about patients.
  • There is a need to improve eye care patient education and health literacy, access to care, and the workforce.
  • There is a need to create continuous improvement system data and to address gaps in disparities research.

Mildred M.G. Olivier, MD
E: molivier@psm.edu
Olivier is associate dean of the School of Medicine at Ponce Health Sciences University, St Louis, Missouri, and has no financial disclosures relevant to this subject matter.
References:
1. Social Determinants of Health. US Department of Health and Human Services. Accessed September 6, 2023. https://health.gov/healthypeople/priority-areas/social-determinants-health.
2. Elam AR, Tseng VL, Rodriguez TM, et al; American Academy of Ophthalmology Taskforce on Disparities in Eye Care. Disparities in vision health and eye care. Ophthalmology. 2022;129(10):e89-e113. doi:10.1016/j.ophtha.2022.07.010
3. Ervin AM, Solomon SD, Shoge RY. Access to eye care in the United States: evidence-informed decision-making is key to improving access for underserved populations. Ophthalmology. 2022;129(10):1079-1080. doi:10.1016/j.ophtha.2022.07.011
Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.